

David E Fisher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5031828/publications.pdf>

Version: 2024-02-01

195
papers

27,750
citations

8208

78
h-index

6686

161
g-index

202
all docs

202
docs citations

202
times ranked

32519
citing authors

#	ARTICLE	IF	CITATIONS
1	Dual Targeting with EZH2 Inhibitor and STING Agonist to Treat Melanoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1004-1006.	0.3	2
2	Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2022, 17, 16.	4.4	8
3	Topical therapy for regression and melanoma prevention of congenital giant nevi. <i>Cell</i> , 2022, 185, 2071-2085.e12.	13.5	13
4	Treatment of Advanced Melanoma in 2020 and Beyond. <i>Journal of Investigative Dermatology</i> , 2021, 141, 23-31.	0.3	193
5	Skin pigmentation and its control: From ultraviolet radiation to stem cells. <i>Experimental Dermatology</i> , 2021, 30, 560-571.	1.4	74
6	Biology of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 29-56.	0.9	40
7	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 2678-2697.	3.2	53
8	Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	54
9	The Melanocyte Lineage Factor miR-211 Promotes BRAFV600E Inhibitor Resistance. <i>Journal of Investigative Dermatology</i> , 2021, 141, 250-252.	0.3	1
10	Stress-associated ectopic differentiation of melanocyte stem cells and ORS amelanotic melanocytes in an ex vivo human hair follicle model. <i>Experimental Dermatology</i> , 2021, 30, 578-587.	1.4	12
11	CYP27A1-dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism. <i>Cell Chemical Biology</i> , 2021, 28, 1407-1419.e6.	2.5	11
12	Reduced MC4R signaling alters nociceptive thresholds associated with red hair. <i>Science Advances</i> , 2021, 7, .	4.7	7
13	Epitope Spreading and the Efficacy of Immune Checkpoint Inhibition in Cancer. <i>International Journal of Oncology Research</i> , 2021, 4, .	0.1	2
14	Vitamin D deficiency exacerbates UV/endorphin and opioid addiction. <i>Science Advances</i> , 2021, 7, .	4.7	16
15	NNT mediates redox-dependent pigmentation via a UVB- and MITF-independent mechanism. <i>Cell</i> , 2021, 184, 4268-4283.e20.	13.5	35
16	MFN2 Stabilization: A Bridge for Endoplasmic Reticulum Stress Sensitivity in Melanoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2782-2784.	0.3	0
17	Melanocortin 1 receptor is dispensable for acute stress induced hair graying in mice. <i>Experimental Dermatology</i> , 2021, 30, 572-577.	1.4	6
18	G9a: An Emerging Epigenetic Target for Melanoma Therapy. <i>Epigenomes</i> , 2021, 5, 23.	0.8	8

#	ARTICLE	IF	CITATIONS
19	SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis. <i>Cancer Research</i> , 2021, 81, 6131-6141.	0.4	31
20	Commentary on NNT Mediates Redox-Dependent Pigmentation a UVB-And MITF-Independent Mechanism.. <i>Journal of Cell Science & Therapy</i> , 2021, 12, .	0.3	0
21	A ROCK inhibitor promotes keratinocyte survival and paracrine secretion, enhancing establishment of primary human melanocytes and melanocyte-keratinocyte co-cultures. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 16-29.	1.5	7
22	Hormones and Hormone Precursors of the Skin. , 2020, , 531-556.		1
23	Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	28
24	Perioperative Serum 25-Hydroxyvitamin D Levels as a Predictor of Postoperative Opioid Use and Opioid Use Disorder: a Cohort Study. <i>Journal of General Internal Medicine</i> , 2020, 35, 2545-2552.	1.3	7
25	Topical treatment strategies to manipulate human skin pigmentation. <i>Advanced Drug Delivery Reviews</i> , 2020, 153, 65-71.	6.6	35
26	FOXD3 Regulates VISTA Expression in Melanoma. <i>Cell Reports</i> , 2020, 30, 510-524.e6.	2.9	42
27	Hyperactivation of sympathetic nerves drives depletion of melanocyte stem cells. <i>Nature</i> , 2020, 577, 676-681.	13.7	158
28	Rational Combination Therapy for Melanoma with Dinaciclib by Targeting BAK-Dependent Cell Death. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 627-636.	1.9	10
29	Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis. <i>Cancer Discovery</i> , 2020, 10, 980-997.	7.7	44
30	Biology of Melanocytes and Primary Melanoma. , 2020, , 3-40.		4
31	Neural crest state activation in NRAS driven melanoma, but not in NRAS-driven melanocyte expansion. <i>Developmental Biology</i> , 2019, 449, 107-114.	0.9	19
32	<scp>MITF</scp> and <scp>UV</scp> responses in skin: From pigmentation to addiction. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 224-236.	1.5	84
33	The Biology of Pigmentation. , 2019, , 21-50.		0
34	Sun exposure and protection practices in children after allogeneic hematopoietic stem cell transplantation: A Survey-Based Cross-Sectional Cohort Study. <i>Pediatric Dermatology</i> , 2019, 36, 882-886.	0.5	0
35	Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. <i>Immunity</i> , 2019, 50, 1498-1512.e5.	6.6	406
36	Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFN γ pathways. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 549-562.	12.5	72

#	ARTICLE	IF	CITATIONS
37	Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. <i>Nature Communications</i> , 2019, 10, 5157.	5.8	46
38	Local genomic features predict the distinct and overlapping binding patterns of the bHLH-Zip family oncoproteins MITF and MYC-MAX. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 500-509.	1.5	13
39	The lncRNA RMEL3 protects immortalized cells from serum withdrawal-induced growth arrest and promotes melanoma cell proliferation and tumor growth. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 303-314.	1.5	17
40	Microphthalmia-associated transcription factor phosphorylation: Cross talk between GSK3 and MAPK signaling. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 345-347.	1.5	3
41	Lineage-specific control of TFIH by MITF determines transcriptional homeostasis and DNA repair. <i>Oncogene</i> , 2019, 38, 3616-3635.	2.6	17
42	Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. <i>Cancer</i> , 2019, 125, 18-44.	2.0	29
43	Biology of Melanocytes and Primary Melanoma. , 2019, , 1-38.		0
44	Nonmalignant late cutaneous changes after allogeneic hematopoietic stem cell transplant in children. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 230-237.	0.6	7
45	MSX1-Induced Neural Crest-Like Reprogramming Promotes Melanoma Progression. <i>Journal of Investigative Dermatology</i> , 2018, 138, 141-149.	0.3	29
46	miRNA-211 stops the clock. <i>Non-coding RNA Investigation</i> , 2018, 2, 25-25.	0.6	1
47	GENE-18. DIVERGENT CLONAL EVOLUTION OF MELANOMA BRAIN METASTASES DURING TREATMENT WITH IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, vi106-vi107.	0.6	0
48	ROCK inhibitor enhances the growth and migration of BRAF-mutant skin melanoma cells. <i>Cancer Science</i> , 2018, 109, 3428-3437.	1.7	36
49	Targeting the (Un)differentiated State of Cancer. <i>Cancer Cell</i> , 2018, 33, 793-795.	7.7	5
50	Pathways in melanoma development. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 68-76.	0.1	4
51	Salt-Inducible Kinases: Physiology, Regulation by cAMP, and Therapeutic Potential. <i>Trends in Endocrinology and Metabolism</i> , 2018, 29, 723-735.	3.1	92
52	The Biology of Pigmentation. , 2018, , 1-30.		1
53	The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. <i>Laboratory Investigation</i> , 2017, 97, 649-656.	1.7	197
54	Tfe3 and Tfeb Transcriptionally Regulate Peroxisome Proliferator-Activated Receptor β 2 Expression in Adipocytes and Mediate Adiponectin and Glucose Levels in Mice. <i>Molecular and Cellular Biology</i> , 2017, 37, .	1.1	17

#	ARTICLE	IF	CITATIONS
55	Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. <i>Clinical Cancer Research</i> , 2017, 23, 4680-4692.	3.2	8
56	The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i> -Mutant Cancers and Potentiates NAD ⁺ Depletion-Mediated Cytotoxicity. <i>Cancer Research</i> , 2017, 77, 4102-4115.	0.4	74
57	Immune and molecular correlates in melanoma treated with immune checkpoint blockade. <i>Cancer</i> , 2017, 123, 2143-2153.	2.0	119
58	A UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin. <i>Cell Reports</i> , 2017, 19, 2177-2184.	2.9	59
59	The melanoma-linked <i>MC1R</i> influences dopaminergic neuron survival. <i>Annals of Neurology</i> , 2017, 81, 395-406.	2.8	41
60	MYO5A Gene Is a Target of MITF in Melanocytes. <i>Journal of Investigative Dermatology</i> , 2017, 137, 985-989.	0.3	9
61	Signaling and Immune Regulation in Melanoma Development and Responses to Therapy. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 75-102.	9.6	30
62	In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. <i>Nature</i> , 2017, 547, 413-418.	13.7	792
63	Topical ROR Inverse Agonists Suppress Inflammation in Mouse Models of Atopic Dermatitis and Acute Irritant Dermatitis. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2523-2531.	0.3	32
64	Hair repigmentation associated with the use of brentuximab. <i>JAAD Case Reports</i> , 2017, 3, 563-565.	0.4	9
65	Negative Regulation of Skin Pigmentation in Three-Dimensional Reconstructs by Adipose-Derived Mesenchymal Cells. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2464-2466.	0.3	1
66	Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6157-E6165.	3.3	90
67	Non-Euclidean phasor analysis for quantification of oxidative stress in ex vivo human skin exposed to sun filters using fluorescence lifetime imaging microscopy. <i>Journal of Biomedical Optics</i> , 2017, 22, 1.	1.4	17
68	Transcriptional Regulation in Melanoma. , 2017, , 95-117.		0
69	Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and \pm -Mangostin. <i>PLoS ONE</i> , 2016, 11, e0155217.	1.1	14
70	In vivo coherent Raman imaging of the melanomagenesis-associated pigment pheomelanin. <i>Scientific Reports</i> , 2016, 6, 37986.	1.6	33
71	Red Hair, Light Skin, and UV-Independent Risk for Melanoma Development in Humans. <i>JAMA Dermatology</i> , 2016, 152, 751.	2.0	24
72	Metastatic melanoma and immunotherapy. <i>Clinical Immunology</i> , 2016, 172, 105-110.	1.4	43

#	ARTICLE	IF	CITATIONS
73	The state of melanoma: challenges and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 404-416.	1.5	77
74	Bioinformatic Analysis of Gene Expression for Melanoma Treatment. <i>Journal of Investigative Dermatology</i> , 2016, 136, 2342-2344.	0.3	6
75	A phase I trial of panobinostat (<sc>LBH</sc>589) in patients with metastatic melanoma. <i>Cancer Medicine</i> , 2016, 5, 3041-3050.	1.3	51
76	Immunotherapy in the Precision Medicine Era: Melanoma and Beyond. <i>PLoS Medicine</i> , 2016, 13, e1002196.	3.9	21
77	Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1820-1828.	0.3	46
78	Transcription Factor Tfe3 Directly Regulates Pgcâ€¹alpha in Muscle. <i>Journal of Cellular Physiology</i> , 2015, 230, 2330-2336.	2.0	33
79	ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM. <i>Molecular Cancer Research</i> , 2015, 13, 1206-1217.	1.5	44
80	Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. <i>Cancer Cell</i> , 2015, 28, 773-784.	7.7	327
81	Authors' Reply. <i>American Journal of Pathology</i> , 2015, 185, 2070.	1.9	1
82	FHL2 switches MITF from activator to repressor of Erbin expression during cardiac hypertrophy. <i>International Journal of Cardiology</i> , 2015, 195, 85-94.	0.8	15
83	Metabolic Vulnerability in Melanoma: A ME2 (Me Too) Story. <i>Journal of Investigative Dermatology</i> , 2015, 135, 657-659.	0.3	3
84	Melanoma. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15003.	18.1	417
85	Biologic Activity of Autologous, Granulocyteâ€¹Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. <i>Clinical Cancer Research</i> , 2015, 21, 3178-3186.	3.2	34
86	Precision medicine for cancer with next-generation functional diagnostics. <i>Nature Reviews Cancer</i> , 2015, 15, 747-756.	12.8	466
87	Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy. <i>JAMA Oncology</i> , 2015, 1, 1340.	3.4	63
88	Label-free DNA imaging in vivo with stimulated Raman scattering microscopy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 11624-11629.	3.3	225
89	A Novel Role for Microphthalmia-Associated Transcription Factorâ€¹Regulated Pigment Epithelium-Derived Factor during Melanoma Progression. <i>American Journal of Pathology</i> , 2015, 185, 252-265.	1.9	17
90	Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. <i>PLoS ONE</i> , 2015, 10, e0140310.	1.1	39

#	ARTICLE	IF	CITATIONS
91	Pathways and therapeutic targets in melanoma. <i>Oncotarget</i> , 2014, 5, 1701-1752.	0.8	202
92	Tanning as a substance abuse. <i>Communicative and Integrative Biology</i> , 2014, 7, e971579.	0.6	4
93	The Impact of MITF on Melanoma Development: News from Bench and Bedside. <i>Journal of Investigative Dermatology</i> , 2014, 134, 16-17.	0.3	11
94	Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2014, 2, 643-654.	1.6	226
95	Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics. <i>PLoS ONE</i> , 2014, 9, e101286.	1.1	42
96	UV Signaling Pathways within the Skin. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2080-2085.	0.3	128
97	High-throughput, high-content screening for novel pigmentation regulators using a keratinocyte/melanocyte co-culture system. <i>Experimental Dermatology</i> , 2014, 23, 125-129.	1.4	13
98	The melanoma revolution: From UV carcinogenesis to a new era in therapeutics. <i>Science</i> , 2014, 346, 945-949.	6.0	328
99	UV and melanoma: the TP53 link. <i>Cell Research</i> , 2014, 24, 1157-1158.	5.7	6
100	The roles of microphthalmia-associated transcription factor and pigmentation in melanoma. <i>Archives of Biochemistry and Biophysics</i> , 2014, 563, 28-34.	1.4	109
101	Skin β -Endorphin Mediates Addiction to UV Light. <i>Cell</i> , 2014, 157, 1527-1534.	13.5	254
102	Melanocyte stem cells as potential therapeutics in skin disorders. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1569-1579.	1.4	41
103	A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors. <i>Cancer Discovery</i> , 2014, 4, 816-827.	7.7	448
104	Isolation and Molecular Characterization of Circulating Melanoma Cells. <i>Cell Reports</i> , 2014, 7, 645-653.	2.9	91
105	Molecular Pathways: BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation. <i>Clinical Cancer Research</i> , 2014, 20, 2257-2263.	3.2	79
106	Understanding the Biology of Melanoma and Therapeutic Implications. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 437-453.	0.9	33
107	Monitoring Repair of UV-Induced 6-4-Photoproducts with a Purified DDB2 Protein Complex. <i>PLoS ONE</i> , 2014, 9, e85896.	1.1	11
108	PGC-1 Coactivators Regulate MITF and the Tanning Response. <i>Molecular Cell</i> , 2013, 49, 145-157.	4.5	84

#	ARTICLE	IF	CITATIONS
109	BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2013, 19, 1225-1231.	3.2	832
110	Targeting melanoma by small molecules: challenges ahead. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 464-469.	1.5	10
111	Oncogenic BRAF Regulates Oxidative Metabolism via PGC1 β and MITF. <i>Cancer Cell</i> , 2013, 23, 302-315.	7.7	689
112	<i>BCL2A1</i> is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 4321-4326.	3.3	200
113	Developing melanoma therapeutics: overview and update. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2013, 5, 257-271.	6.6	13
114	How does pheomelanin synthesis contribute to melanomagenesis?. <i>BioEssays</i> , 2013, 35, 672-676.	1.2	75
115	Myosin-Va Contributes to Manifestation of Malignant-Related Properties in Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2809-2812.	0.3	17
116	Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. <i>Journal of Clinical Oncology</i> , 2013, 31, 3182-3190.	0.8	530
117	Disproportionate Burden of Melanoma Mortality in Young US Men. <i>JAMA Dermatology</i> , 2013, 149, 903.	2.0	21
118	Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9080-9080.	0.8	1
119	YY1 Regulates Melanocyte Development and Function by Cooperating with MITF. <i>PLoS Genetics</i> , 2012, 8, e1002688.	1.5	45
120	An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. <i>Nature</i> , 2012, 491, 449-453.	13.7	406
121	From genes to drugs: targeted strategies for melanoma. <i>Nature Reviews Cancer</i> , 2012, 12, 349-361.	12.8	323
122	Melanoma: from mutations to medicine. <i>Genes and Development</i> , 2012, 26, 1131-1155.	2.7	415
123	A Melanoma Molecular Disease Model. <i>PLoS ONE</i> , 2011, 6, e18257.	1.1	77
124	A new era: melanoma genetics and therapeutics. <i>Journal of Pathology</i> , 2011, 223, 242-251.	2.1	107
125	Hypoxia-induced transcriptional repression of the melanoma-associated oncogene <i>MITF</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, E924-33.	3.3	101
126	Biology and Clinical Relevance of the Microphthalmia Family of Transcription Factors in Human Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3474-3482.	0.8	124

#	ARTICLE	IF	CITATIONS
127	Dual roles of lineage restricted transcription factors. <i>Transcription</i> , 2011, 2, 19-22.	1.7	41
128	A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. <i>Nature</i> , 2011, 480, 99-103.	13.7	413
129	Regulation of MITF stability by the USP13 deubiquitinase. <i>Nature Communications</i> , 2011, 2, 414.	5.8	86
130	Central role for cAMP signaling in pigmentation and UV resistance. <i>Cell Cycle</i> , 2011, 10, 8-9.	1.3	29
131	New Strategies in Metastatic Melanoma: Oncogene-Defined Taxonomy Leads to Therapeutic Advances. <i>Clinical Cancer Research</i> , 2011, 17, 4922-4928.	3.2	34
132	Transcriptional Regulation in Melanoma. , 2011, , 79-103.		1
133	How Sunlight Causes Melanoma. <i>Current Oncology Reports</i> , 2010, 12, 319-326.	1.8	104
134	Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit. <i>Genes and Development</i> , 2010, 24, 2276-2281.	2.7	68
135	An Oncogenic Role for <i>ETV1</i> in Melanoma. <i>Cancer Research</i> , 2010, 70, 2075-2084.	0.4	107
136	Identification of the Receptor Tyrosine Kinase c-Met and Its Ligand, Hepatocyte Growth Factor, as Therapeutic Targets in Clear Cell Sarcoma. <i>Cancer Research</i> , 2010, 70, 639-645.	0.4	100
137	Indoor Tanning Science, Behavior, and Policy. <i>New England Journal of Medicine</i> , 2010, 363, 901-903.	13.9	130
138	Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function. <i>Cancer Research</i> , 2010, 70, 5213-5219.	0.4	659
139	Intronic miR-211 Assumes the Tumor Suppressive Function of Its Host Gene in Melanoma. <i>Molecular Cell</i> , 2010, 40, 841-849.	4.5	246
140	Lineage-Specific Transcriptional Regulation of DICER by MITF in Melanocytes. <i>Cell</i> , 2010, 141, 994-1005.	13.5	113
141	Key Roles for Transforming Growth Factor β^2 in Melanocyte Stem Cell Maintenance. <i>Cell Stem Cell</i> , 2010, 6, 130-140.	5.2	197
142	Shin-Ichi Nishikawa MD, PhD. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 683-683.	1.5	0
143	Lighting a path to pigmentation: mechanisms of MITF induction by UV. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 741-745.	1.5	67
144	Specification and loss of melanocyte stem cells. <i>Seminars in Cell and Developmental Biology</i> , 2009, 20, 111-116.	2.3	23

#	ARTICLE	IF	CITATIONS
145	Transcriptional Regulation in Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 447-465.	0.9	21
146	Scientific and social controversies regarding UV and pigmentation: the beneficial effects of UV irradiance outweighs the risks - a reply. <i>Pigment Cell and Melanoma Research</i> , 2009, 22, 139-139.	1.5	0
147	Preface. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, xiii-xiv.	0.9	0
148	Indoor ultraviolet tanning and skin cancer: health risks and opportunities. <i>Current Opinion in Oncology</i> , 2009, 21, 144-149.	1.1	72
149	Notch and Melanocytes: Diverse Outcomes from a Single Signal. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2571-2574.	0.3	25
150	Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. <i>Pigment Cell and Melanoma Research</i> , 2008, 21, 457-463.	1.5	104
151	UV and pigmentation: molecular mechanisms and social controversies. <i>Pigment Cell and Melanoma Research</i> , 2008, 21, 509-516.	1.5	88
152	Major Response to Imatinib Mesylate in <i>KIT</i> -Mutated Melanoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 2046-2051.	0.8	430
153	Epistatic connections between microphthalmia-associated transcription factor and endothelin signaling in Waardenburg syndrome and other pigmentary disorders. <i>FASEB Journal</i> , 2008, 22, 1155-1168.	0.2	78
154	Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma. <i>Clinical Cancer Research</i> , 2008, 14, 7726-7732.	3.2	126
155	TFE3 Fusions Activate MET Signaling by Transcriptional Up-regulation, Defining Another Class of Tumors as Candidates for Therapeutic MET Inhibition. <i>Cancer Research</i> , 2007, 67, 919-929.	0.4	275
156	Central Role of p53 in the Suntan Response and Pathologic Hyperpigmentation. <i>Cell</i> , 2007, 128, 853-864.	13.5	552
157	High-throughput mapping of the chromatin structure of human promoters. <i>Nature Biotechnology</i> , 2007, 25, 244-248.	9.4	300
158	Melanocyte biology and skin pigmentation. <i>Nature</i> , 2007, 445, 843-850.	13.7	1,048
159	MITF: master regulator of melanocyte development and melanoma oncogene. <i>Trends in Molecular Medicine</i> , 2006, 12, 406-414.	3.5	993
160	Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. <i>Nature</i> , 2006, 443, 340-344.	13.7	302
161	Oncogenic MITF dysregulation in clear cell sarcoma: Defining the MiT family of human cancers. <i>Cancer Cell</i> , 2006, 9, 473-484.	7.7	172
162	c-Met Expression Is Regulated by Mitf in the Melanocyte Lineage. <i>Journal of Biological Chemistry</i> , 2006, 281, 10365-10373.	1.6	145

#	ARTICLE	IF	CITATIONS
163	Malignant melanoma: genetics and therapeutics in the genomic era. <i>Genes and Development</i> , 2006, 20, 2149-2182.	2.7	436
164	Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. <i>Nature</i> , 2005, 436, 117-122.	13.7	1,329
165	BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma. <i>Current Biology</i> , 2005, 15, 249-254.	1.8	626
166	Sumoylation of MITF and Its Related Family Members TFE3 and TFEB. <i>Journal of Biological Chemistry</i> , 2005, 280, 146-155.	1.6	128
167	Mechanisms of Hair Graying: Incomplete Melanocyte Stem Cell Maintenance in the Niche. <i>Science</i> , 2005, 307, 720-724.	6.0	984
168	Genomic analysis of the Microphthalmia locus and identification of the MITF-J/Mitf-J isoform. <i>Gene</i> , 2005, 347, 73-82.	1.0	86
169	Transcriptional Regulation of the Melanoma Prognostic Marker Melastatin (TRPM1) by MITF in Melanocytes and Melanoma. <i>Cancer Research</i> , 2004, 64, 509-516.	0.4	191
170	Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. <i>Cancer Cell</i> , 2004, 6, 565-576.	7.7	373
171	Microphthalmia-associated transcription factor: a critical regulator of pigment cell development and survival. <i>Oncogene</i> , 2003, 22, 3035-3041.	2.6	337
172	MLANA/MART1 and SILV/PMEL17/GP100 Are Transcriptionally Regulated by MITF in Melanocytes and Melanoma. <i>American Journal of Pathology</i> , 2003, 163, 333-343.	1.9	266
173	Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 6051-6056.	3.3	238
174	A Tissue-restricted cAMP Transcriptional Response. <i>Journal of Biological Chemistry</i> , 2003, 278, 45224-45230.	1.6	83
175	Identification of Aim-1 as the underwhiteMouse Mutant and Its Transcriptional Regulation by MITF. <i>Journal of Biological Chemistry</i> , 2002, 277, 402-406.	1.6	87
176	Î²-Catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. <i>Journal of Cell Biology</i> , 2002, 158, 1079-1087.	2.3	268
177	Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability. <i>Cell</i> , 2002, 109, 707-718.	13.5	671
178	Sensorineural Deafness and Pigmentation Genes. <i>Neuron</i> , 2001, 30, 15-18.	3.8	83
179	Linkage of M-CSF Signaling to Mitf, TFE3, and the Osteoclast Defect in Mitfmi/mi Mice. <i>Molecular Cell</i> , 2001, 8, 749-758.	4.5	145
180	Microphthalmia: A Signal Responsive Transcriptional Regulator in Development. <i>Pigment Cell & Melanoma Research</i> , 2000, 13, 145-149.	4.0	25

#	ARTICLE	IF	CITATIONS
181	Ser298 of MITF, a mutation site in Waardenburg syndrome type 2, is a phosphorylation site with functional significance. <i>Human Molecular Genetics</i> , 2000, 9, 125-132.	1.4	150
182	Turning p53 on or off: either way may treat cancer. <i>Drug Resistance Updates</i> , 2000, 3, 77-79.	6.5	6
183	c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. <i>Genes and Development</i> , 2000, 14, 301-312.	2.7	435
184	Microphthalmia Transcription Factor. <i>American Journal of Pathology</i> , 1999, 155, 731-738.	1.9	233
185	MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. <i>Nature</i> , 1998, 391, 298-301.	13.7	588
186	Microphthalmia Gene Product as a Signal Transducer in cAMP-Induced Differentiation of Melanocytes. <i>Journal of Cell Biology</i> , 1998, 142, 827-835.	2.3	456
187	Lineage-specific Signaling in Melanocytes. <i>Journal of Biological Chemistry</i> , 1998, 273, 17983-17986.	1.6	174
188	Î±-Melanocyte-stimulating Hormone Signaling Regulates Expression of microphthalmia, a Gene Deficient in Waardenburg Syndrome. <i>Journal of Biological Chemistry</i> , 1998, 273, 33042-33047.	1.6	202
189	Age-resolving Osteopetrosis: A Rat Model Implicating Microphthalmia and the Related Transcription Factor TFE3. <i>Journal of Experimental Medicine</i> , 1998, 187, 775-785.	4.2	88
190	atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. <i>Nature Genetics</i> , 1997, 16, 397-401.	9.4	216
191	Extensive apoptosis in ductal carcinoma in situ of the breast. , 1996, 77, 1831-1835.		54
192	Extensive apoptosis in ductal carcinoma in situ of the breast. , 1996, 77, 1831.		2
193	Pre-bending of a promoter sequence enhances affinity for the TATA-binding factor. <i>Nature</i> , 1995, 373, 724-727.	13.7	189
194	Chest wall recurrence of ductal carcinoma in situ of the breast after mastectomy. <i>Cancer</i> , 1993, 71, 3025-3028.	2.0	18
195	Diffuse large cell lymphoma with discordant bone marrow histology. Clinical features and biological implications. <i>Cancer</i> , 1989, 64, 1879-1887.	2.0	48